SFTs were investigated for STAT6 immunoreactivity using a monoclonal antibody. STAT6 immunocytochemistry was also investigated in schwannomas and spindle cell lipomas. Cytopathologic and clinical characteristics were described.
INTRODUCTION
Solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms. Although the cell type of origin is unknown, SFTs frequently appear in close relation to the pleura, the meninges, or in soft tissue. 1, 2 Historically, there has been a distinction between SFTs and hemangiopericytomas (HPCs). The discovery of a mutual underlying inversion on chromosome 12q13, resulting in the NGFI-A-binding protein 2 (NAB2)-signal transducer and activator of transcription 6 (STAT6) fusion gene, recognized them as a single entity and is now considered the hallmark of SFTs. [3] [4] [5] [6] Subsequent studies have demonstrated that STAT6 c-terminus nuclear immunoreactivity is a viable surrogate marker for the fusion gene and is both a sensitive and specific marker in the histopathologic diagnosis of SFTs. 5, 7, 8 The histologic presentation of SFT varies, but it is classically composed of areas with variable cellularity and with spindle or oval cells in a patternless configuration, collagenous stroma, and a staghorn-branching vascular pattern. Most SFTs exhibit strong immunoreactivity for CD34 (a hematopoietic progenitor cell antigen), but similar expression may be observed among other spindle cell tumors with an SFT-like histologic pattern, eg, gastrointestinal stromal tumor, deep fibrous histiocytoma, neurofibroma, soft tissue perineuroma, dermatofibrosarcoma protuberans, and spindle cell lipoma. Because SFTs constitute a difficult diagnosis on histology, and there are several histologic mimickers, the identification of nuclear STAT6 immunoreactivity or the NAB2-STAT6 fusion gene will increase the diagnostic accuracy of these lesions. SFTs are rarely metastasizing tumors. 9 Although there are no definite criteria for malignancy, the 2013 World Health Organization classification recognizes that hypercellularity, moderate cellular atypia, >4 mitoses per 10 high-power fields, necrosis, and infiltrative margins are indicative of malignancy. 9 Recently, Demicco et al suggested a risk-stratification model (low, moderate, or high risk) of primary tumors based on patient age, tumor size, and mitotic rate. 10 In trained hands, fine-needle aspiration (FNA) cytology is a safe method for the diagnosis of soft tissue tumors and will allow an accurate and reliable preoperative diagnosis to ensure an adequate clinical therapeutic approach. Only a few studies have described the cytopathologic features of benign and malignant extracranial SFTs. [11] [12] [13] [14] [15] [16] In those reports, significant proportion of tumors had an inaccurate preoperative diagnosis, emphasizing the need for a reliable diagnostic marker in the FNA diagnosis of SFTs. Although STAT6 immunohistochemistry has been established as a diagnostic marker in surgical specimens, to our knowledge, no study has yet evaluated its application on FNA material. For the current study, we reviewed FNA smears from histologically diagnosed extracranial SFTs at our institution during the past 24 years, including 19 benign and 6 malignant SFTs as well as 2 soft tissue metastases from 27 patients. The histopathologic diagnoses of all surgical specimens were validated using STAT6 immunohistochemistry, and available formalin-fixed FNA specimens were analyzed retrospectively for STAT6 immunoreactivity.
MATERIALS AND METHODS

Patient Samples
The archives of the Department of Clinical Pathology and Cytology at Karolinska University Hospital were searched for cases of SFT/hemangiopericytomas from January 1993 to January 2017. Inclusion criteria were a histopathologic diagnosis of SFT with both cytologic and histologic material/specimens available for review. All surgical specimens were reviewed and classified as malignant or benign according to World Health Organization 2013 criteria and were classified according risk criteria suggested by Demicco et al. 10 All cytologic smear evaluations were reviewed by a double-blinded panel of 3 senior cytopathologists. Cytologic smears were air dried and stained with May-Grunewald Giemsa. When available, formalin-fixed smears were used for retrospective STAT6 immunocytochemistry. Clinical data were available for all patients.
Ethical Permission
This study was approved by the local ethical board. All patients provided informed consent in accordance with the Swedish Biobank law.
STAT6 Immunohistochemistry and Immunocytochemistry
Formalin-fixed, paraffin-embedded tumor tissues were cut into 4-lm sections and stained for STAT6 using monoclonal anti-STAT6 (clone YE361, ab32520; Abcam, Cambridge, UK) at a working dilution of 1:100. Immunostaining was performed using either a Ventana autostainer with cell conditioning 1, pH 8.5 (both from Ventana Medical Systems, Inc., Tucson, Arizona) at our clinical laboratory or by manual immunohistochemistry with the Vectastain Elite avidin-biotin complex horseradish peroxidase kit (ABC HRP Kit; Vector Laboratories, Burlingame, California) and 20 minutes of antigen retrieval by boiling in high pH solution (ethylene diamine tetra acetic acid). For immunohistochemistry, antigen retrieval with low pH buffer yielded generally poor immunoreactivity. A group of histologically verified SFTs was used as a positive control, and a synovial sarcoma sample was used as a negative control.
FNA specimens were stained for STAT6 using the same antibody at 1:50 working concentration and at room temperature for 30 minutes using the Polymer Refine Detection Kit on a Bond-III autostainer (Leica Biosystems, Wetzlar, Germany) at our clinical laboratory. Antigen retrieval was performed for 5 minutes at 100 8C using low pH citrate solution (Leica Biosystems). Available cytologic specimens from histologically verified schwannomas (n 5 2) and spindle cell lipomas (n 5 2) were stained for STAT6 for comparison.
RESULTS
Patient Demographics and Clinical Characteristics
We identified 28 extracranial SFTs from 28 patients who had FNA specimens available, including 19 benign SFTs and 9 malignant SFTs. Three benign and 1 malignant tumors were sampled more than once. One benign SFT and 1 SFT soft tissue metastasis originated from the pleura, and the remaining tumors were extrapleural (soft tissue) SFTs. Clinical data for each case are presented in Supporting Table 1 (see online supporting information).
Patients with benign SFTs had a female overrepresentation (2.8:1 female-to-male ratio) and a median age of 47 years (mean, 52 years; range, 16-87 years). Those with malignant SFTs had a somewhat more equal sex distribution (1.25:1 female-to-male ratio) and an older median age of 62 years (mean, 62 years; range, 36-88 years). The median primary tumor size of benign SFTs was 4.75 cm (average. 6.3; range, 2-16 cm), and malignant SFTs measured a median of 10 cm (average, 11.6 cm; range, 4-21 cm).
Benign extrapleural SFTs (n 5 18) were central (n 5 10) or were located in the extremities (n 5 8). They presented as intramuscular (n 5 9), subcutaneous (n 5 4), retroperitoneal (n 5 2), or paravertebral (n 5 2) tumors; and there was an intra-abdominal local recurrence (n 5 1). Malignant SFTs were central (n 5 3) or were located in extremities (n 5 4). They were localized in intramuscular (n 5 4), retroperitoneal (n 5 1), and intra-abdominal (n 5 1) areas or in soft-tissues on the neck (n 5 1). Two FNA specimens were from metastases in the soft tissues (n 5 1) and an intra-abdominal metastasis from a previous intra-abdominal SFT.
Primary tumors presented as slow-growing, painless lumps (15 of 24 tumors), painful lumps (n 5 2 tumors), or fast-growing lumps (n 5 3); or as localized swellings (n 5 2 tumors); or were identified en passant during radiology (n 5 2) or with metastasis at the time of diagnosis (n 5 1). No patient presented with paraneoplastic hypoglycemia (Doege-Potter syndrome). Most patients with benign SFTs described a lump that had been present for more than 6 months (Supporting Table 1 ; see online supporting information).
Cytopathologic Features
The 19 benign SFTs were diagnosed on FNA cytology as SFTs (n 5 2); mesenchymal tumors not otherwise specified (NOS) (n 5 7); or mesenchymal tumor favoring vascular origin (n 5 3), SFT (n 5 1), neural origin (n 5 1). One tumor was diagnosed on cytology as a spindle cell tumor NOS (n 5 1), and 1 was diagnosed as a local recurrence of SFT (n 5 1). Three were diagnosed with a suspicion of malignancy.
Six primary tumors were histopathologically diagnosed as malignant SFTs. Of these, on FNA cytology, 2 were diagnosed as sarcoma (n 5 1) or favor sarcoma (n 5 1). The remaining tumors were diagnosed as mesenchymal tumors, favoring either SFT (n 5 1), vascular origin (n 5 2), neural origin (n 5 1), or NOS (n 5 1). Two tumors were diagnosed as recurrences of previously diagnosed SFTs. The original FNA cytologic diagnoses are listed in Supporting Table 1 (see online supporting  information) .
Benign SFTs had fairly homogenous cytologic features, presenting with low (26%) to moderate (74%) cellularity and varying presence of hypercellular cohesive clusters (100%). In most tumors, there was a pink, collagenous intercellular stroma (99.5%), and sometimes vessellike structures could be identified (42%). Tumor cells were a mixture of oval, elongated, round, and stellate cells. The presence of a single cellular shape was quite uncommon (11%). All benign SFTs exhibited some degree of naked nuclei (ranging from single cells to abundant cells). Nuclear pleomorphism was absent (58%), scant (37%), or moderate (0.5%). Cytopathologic features are listed in Table 1 , and representative images are provided in Figure 1 .
The tumor that presented as an intra-abdominal recurrence from a previously diagnosed intra-abdominal SFT had cytopathologic features consistent with the benign SFT, with monomorphic oval cells without pleomorphism and a lack of hypercellular clusters or collagenous stroma. The malignant SFTs all exhibited cytopathologic features consistent with benign SFT, but 4 of 7 tumors (57%) had moderate nuclear pleomorphism (which was identified in 1 of 19 benign cases). One had no collagenous stroma, and 1 exhibited round cell morphology with rosette-like formations.
After the initial double-blinded review, the features of malignant and benign SFTs were compared. Although nuclear pleomorphism, mitotic figures, and necrosis (not identified in our material) should be indicative of a malignant phenotype, one-half of malignant tumors exhibited cytopathologic features consistent with benign SFT. It should also be noted that there was no clear association between tumor metastasis and the degree of cellular atypia. Photomicrographs of the cytologic presentation of malignant SFTs and metastases are provided in Figure 2 .
Immunocytochemistry and Immunohistochemistry for STAT6 and Ki67
All included surgical specimens were retrieved for retrospective immunohistochemical analysis and stained strongly for nuclear STAT6 using a monoclonal antibody. Formalin-fixed FNA specimens were available for 5 SFTs, all of which exhibited strong nuclear STAT6 immunoreactivity. Representative microphotographs of immunohistochemistry, immunocytochemistry, and corresponding hematoxylin and eosin-stained and May-Grunewald Giemsa-stained specimens are provided in Figure 3 .
Available formalin-fixed FNA specimens from 2 spindle cell lipomas and 2 schwannomas were stained for STAT6. All specimens exhibited negative nuclear staining and moderate-to-strong cytoplasmic immunoreactivity for STAT6 (Fig. 4) . A subset of cases had been stained immunohistochemically (12 benign and 7 malignant specimens) and/or immunocytochemically (6 benign and 3 malignant specimens) to determine the Ki67 proliferation index as part of the diagnostic workup (Supporting Table 1 ; see online supporting information). Neither the immunohistochemistrybased nor the immunocytochemistry-based Ki67 index could separate benign SFTs (immunohistochemistry: average, 7%; range, 1%-20%) from malignant SFTs (immunohistochemistry: average, 10%; range, 3%-15%). Although immunohistochemistry and immunocytochemistry Ki67 indices were frequently similar, immunocytochemistry underestimated the Ki67 proliferation index in 2 of 8 specimens.
DISCUSSION
FNA cytology is an important tool in the diagnosis of soft tissue tumors. SFT may appear in a wide range of anatomic locations and is acknowledged as a difficult cytopathologic diagnosis. There are limited numbers of smaller series describing the cytopathologic features of these tumors, with a majority originating in the pleura. [11] [12] [13] [14] [15] [16] We reviewed a larger series of histologically verified SFTs diagnosed during a 23-year period at our institution. Most of our cases were soft tissue SFTs. In conjunction with previous studies, we can conclude that pleural and soft tissue SFTs share a similar cytopathologic picture. [12] [13] [14] [15] [16] The largest series of FNA material from histologically diagnosed malignant SFTs (13 tumors in 11 patients) was presented by Bishop and colleagues, 11 who described features of malignant SFT similar to those we observed in dedifferentiated/metastatic tumors (pleomorphism, roundcell features, necrosis and mitotic figures). They suggested that FNA may be prone to sampling error in SFTs if highgrade areas of the tumor are not sampled. This is in line with our finding that one-half of malignant SFTs in our series had cytopathologic features similar to those of benign SFTs.
Retrospective analyses revealed that all SFT FNAs and surgical specimens expressed nuclear STAT6, as determined by a rabbit monoclonal antibody, suggesting that STAT6 FNA immunocytochemistry has a sensitivity similar to that of STAT6 immunohistochemistry in surgical specimens. In 2 larger histologic series of mesenchymal tumors, strong nuclear STAT6 immunoreactivity occasionally was observed in undifferentiated pleomorphic sarcomas, in well differentiated and dedifferentiated liposarcomas, and in a deep fibrous histiocytoma, which could constitute possible diagnostic pitfalls. Weak nuclear immunoreactivity was also observed in patients with desmoid-type fibromatosis, leiomyosarcoma, neurofibroma, synovial sarcoma, and scar tissue. In retrospective series, it was demonstrated that older patients and dedifferentiated components of SFT lose STAT6 immunoreactivity; however, the reported overall sensitivity of strong nuclear STAT6 staining in SFTs is >95%. 7, 17, 18 While evaluating STAT6 antibodies, we observed that the immunoreactivity produced by the monoclonal rabbit antibody in the current study was more robust than the more widely used SC-20 (SC-621) antibody, which is in line with previous publications. 7, 8, 17 We also investigated use of the Ki67 index for assessing malignant potential, but the proliferation index did not help in distinguishing between benign and malignant SFTs. In the current series, 2 cytologic spindle cell tumors (schwannomas and spindle cell lipomas) stained negative for nuclear STAT6 but exhibited moderate-to-strong cytoplasmic immunoreactivity, emphasizing the importance of the correct interpretation of subcellular localization, as in surgical specimens. 17 Previously, CD34 and BCL2 (B-cell lymphoma 2) were used as positive markers for SFTs. Although they are less specific, we believe that these markers still have diagnostic value for the immunocytochemical evaluation of soft tissue tumors when SFT constitutes a differential diagnosis.
In conclusion, SFTs have distinct cytopathologic features. Nuclear STAT6 immunoreactivity very likely increases the diagnostic accuracy of FNA SFT diagnosis. Although findings of distinct nuclear pleomorphism, necrosis, or mitotic figures may indicate a malignancy, SFT grading based on cytology alone is difficult.
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